Introduction:?The potential benefit of statin therapy on patients with atypical chest pain, mild coronary artery disease (CAD) with non-hyperlipidemia has not been established yet. We investigated the association between statin use and risk of all-cause mortality and cardiovascular (CV) event in patients with mild CAD with non-hyperlipidemia.?Hypothesis:?The statin therapy could decrease CV events in patients with mild CAD with non-hyperlipidemia.?Methods:?From 2009 January to 2014 May, total of 723 patients who had (0-50%) mild stenosis on CAG (coronary angiography) from VHS medical center were reviewed retrospectively. All-cause mortality and event free survival were analyzed according to the use of statins. The CV events included all-cause death, coronary revascularization and stroke.?Results:?Mean age of the study population was 67.4±6.5 years and 93.4% were male. The baseline LDL cholesterol (mg/dl) was not different between two groups (96.8±31.5 vs. 91.3±30.9, p＝0.239) but follow-up of LDL cholesterol in statin users was significantly lower than statin non-users (73.5±29.1 vs. 88.1±29.4, p＝0.012). During a mean of 33.5±17.9 months’ follow-up, all-cause death was reported in 19 patients (2.6%), of whom 2(1.4%) were statin users and 17(3%) statin nonusers. The Kaplan-Meier survival and event free survival rate at 3 years were not significantly different between statin users and non-users (98.6±0.1% vs. 97.2±1.1%, p＝0.185 and 96.5±1.5% vs. 94.8±1.1%, p＝0.318). In a multivariate Cox regression analysis, high sensitivity C-reactive protein (hsCRP) remained significantly and independently associated with an increased risk of all-cause mortality and CV events (HR 1.018 [95% CI 1.007 to 1.029], p＝0.001 and HR 1.017 [95% CI 1.008 to 1.026], p＜0.001).?Conclusions:?Statin therapy may have no beneficial effect in CV events in patients with atypical chest pain, mild CAD with non-hyperlipidemia.